Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

GW Pharma begins phase IIa trial of cannabinoids in type 2 diabetes

Oct. 5, 2010

Pierre Fabre Medicament discloses new 11-beta-HSD1 inhibitors

Oct. 5, 2010

Phase III trial of lixisenatide in combination with basal insulin meets primary endpoint

Oct. 4, 2010

FDA grants type B meeting to Repros to discuss phase III protocols for Androxal

Oct. 4, 2010

NNC-126-0083 is well tolerated in adults and children with growth hormone deficiency

Oct. 4, 2010

Conbriza is approved in Spain for postmenopausal osteoporosis

Oct. 1, 2010

Enrollment complete in phase IIa trial of XOMA-052 in type 2 diabetes

Oct. 1, 2010

SAR-707 reveals limitations of acyl-CoA desaturase inhibition in metabolic disorders

Oct. 1, 2010

Elixir Pharmaceuticals claims new ghrelin receptor modulators

Sep. 30, 2010

KAI-4169 enters phase Ib trial for secondary hyperparathyroidism in ESRD

Sep. 30, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...